Reactive oxygen species-responsive nano gel as a carrier, combined with photothermal therapy and photodynamic therapy for the treatment of brucellosis
Journal of Biomaterials Applications · 2025-02 · 39 (7) · 748-761
DOI: 10.1177/08853282241279340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomaterials Applications, online erschienen am 23.10.2024. Verfasst von Yuchang Qin und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering/State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, Shihezi University, S…. Hauptthemen laut MEDLINE: Photochemotherapy, Reactive Oxygen Species, Brucellosis, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Shihezi Uni.Project, International Cooperation Project from CSC, 2023 Key Field Research Project.
Abstract (Originalsprache)
Brucellosis is an intracellular infectious disease that is primarily treated with antibacterial therapy. However, most antibacterial drugs struggle to penetrate the cell membrane and may be excluded or inactivated within the cell. In a recent study, researchers developed a nanogel coated with polydopamine (PDA) that responds to reactive oxygen species (ROS) and has enhanced adhesion properties. This nanogel encapsulates photosensitized zinc phthalocyanine (ZnPc) and an antibacterial drug, and is further modified with folic acid (FA) for active targeting. The resulting ROS-responsive nanogel, termed PDA@PMAA@ZnPc@DH-FA, can reach temperatures up to 50°C under near-infrared light, leading to a 72.1% improvement in drug release through increased ROS production. Cell staining confirmed a cell survival rate above 75%, with a low hemolysis rate of only 4.633%, indicating excellent biocompatibility. Furthermore, the study’s results showed that the nanogel exhibited stronger killing effects against Brucella compared to administering the drug alone. Under near-infrared irradiation, the nanogel achieved a bacteriostatic rate of 99.8%. The combined approach of photothermal therapy and photodynamic therapy offers valuable insights for treating Brucella.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering/State Key Laboratory Incubation Base for Green Processing of Chemical Engineering, Shihezi University, Shihezi, China.
- Department of Materials Science and Engineering, Monash University, Clayton, VIC, Australia.
- Lab of Low-Dimensional Materials Chemistry, Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China.
ORCID-Profile: Yuchang Qin, Zhiyong Liu, Shengchao Yang
Förderung
- Shihezi Uni.Project
- International Cooperation Project from CSC
- 2023 Key Field Research Project
Zitieren
APA
Qin, Y., Xu, Y., Lin, F., Qiu, Y., Luo, Y., Lv, X., Liu, T., Li, Y., Liu, Z., & Yang, S. (2025). Reactive oxygen species-responsive nano gel as a carrier, combined with photothermal therapy and photodynamic therapy for the treatment of brucellosis. Journal of Biomaterials Applications, 39(7), 748-761. https://doi.org/10.1177/08853282241279340
Vancouver
Qin Y, Xu Y, Lin F, Qiu Y, Luo Y, Lv X, et al. Reactive oxygen species-responsive nano gel as a carrier, combined with photothermal therapy and photodynamic therapy for the treatment of brucellosis. Journal of Biomaterials Applications. 2025;39(7):748-761. doi:10.1177/08853282241279340
BibTeX
@article{Qin2025,
author = {Qin, Yuchang and Xu, Yuanyuan and Lin, Fuli and Qiu, Yinwei and Luo, Yujie and Lv, Xuan and Liu, Tianyu and Li, Yongsheng and Liu, Zhiyong and Yang, Shengchao},
title = {Reactive oxygen species-responsive nano gel as a carrier, combined with photothermal therapy and photodynamic therapy for the treatment of brucellosis},
journal = {Journal of Biomaterials Applications},
year = {2025},
volume = {39},
number = {7},
pages = {748--761},
doi = {10.1177/08853282241279340}
}
EUVIMED